MDXG Stock Recent News
MDXG LATEST HEADLINES
MARIETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the first quarter ended March 31, 2023 after the market close on Tuesday, May 2, 2023. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day.
MiMedx Group, Inc. (NASDAQ:MDXG ) Q4 2022 Results Conference Call February 28, 2023 5:00 PM ET Company Participants Matt Notarianni - Head, IR Joe Capper - CEO Pete Carlson - CFO Conference Call Participants Anthony Petrone - Mizuho Group Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon, and thank you for standing by.
MiMedx Group, Inc. (NASDAQ:MDXG ) Q3 2022 Earnings Conference Call November 2, 2022 5:00 PM ET Company Participants Matt Notarianni – Head-Investor Relations Todd Newton – Interim Chief Executive Officer Pete Carlson – Chief Financial Officer Rohit Kashyap – President-Wound and Surgical Robert Stein – President-Regenerative Medicine Conference Call Participants Anthony Petrone – Mizuho Group RK – H.C. Wainwright Carl Byrnes – Northland Capital John Vandermosten – Zacks Operator Good afternoon and thank you for standing by.
MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on Wednesday, August 10, 2022 at 3:00 p.m. Eastern Time. Institutional investors interested in a meeting with senior management may contact their Canaccord Genuity representative.
MiMedx Group, Inc. (NASDAQ:MDXG ) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Jack Howarth – Senior Vice President-Investor Relations Tim Wright – Chief Executive Officer Pete Carlson – Chief Financial Officer Rohit Kashyap – President Wound Care and Surgical Robert Stein – President, Regenerative Medicine and Biologics Innovation Conference Call Participants Anthony Petrone – Mizuho Group RK – H.C. Wainwright Carl Byrnes – Northland Capital Markets John Vandermosten – Zacks Operator Greetings, and welcome to the MiMedx Group Second Quarter 2022 Operational and Financial Results Conference Call.
MARIETTA, Ga., July 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the second quarter ended June 30, 2022, after the market close on Tuesday, August 2, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results on Wednesday, August 3, 2022, beginning at 8:30 a.m. Eastern Time.
MARIETTA, Ga., March 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the Canaccord Genuity Musculoskeletal Conference in Chicago on Tuesday, March 22 at 10:30 AM CDT / 11:30 AM EDT. Institutional investors interested in a meeting with management during the conference may reach out to their Canaccord Genuity representative.
MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q4 2021 Results - Earnings Call Transcript
MARIETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the fourth quarter ended December 31, 2021 after the market close on Monday, February 28, 2022. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day.
MARIETTA, Ga., Jan. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.